A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma

ConclusionThis study suggests that autologous RAK cell immunotherapy is safe and has clinical activity in previously treated mRCC patients. The improvement in peripheral blood immune profiling after RAK cell infusion highlights its potential as a cancer treatment. Further investigation is necessary to understand its clinical utility.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research